Skip to main content
All lobbying filings

JEFFREY J. KIMBELL & ASSOCIATES, INC.

JEFFREY J. KIMBELL & ASSOCIATES, INC. filed a Q3 report for ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY on October 20, 2025, reporting $20,000 in lobbying income.

Lobbying for ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY · Issues related to pharmaceutical drugs

All filings by JEFFREY J. KIMBELL & ASSOCIATES, INC. · Everything ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$20,000
What the client paid this registrant for the period.
Client based in
Pennsylvania

Official filing document

 Lobbyists on this filing 5
  • KEITH STUDDARD
    Previously held: Legislative Director, Rep. Marsha Blackburn
  • JOHN HERZOG
    Previously held: Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President
  • JOHN R RAY
    Previously held: Legislative Assistant, Rep. Mike Kelly
  • LAURA KEMPER
    Previously held: Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services
  • BRETT MEEKS
    Previously held: Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

Issues related to Domestic manufacturing; Issues related to 340B; implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience; Issues related to tariffs; Issues related to 503B Compounding.

Pharmacy

Issues related to Domestic manufacturing; Issues related to 340B; implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience; Issues related tariffs; Issues related to 503B Compounding

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem